Detalles de la búsqueda
1.
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.
Clin Infect Dis
; 71(12): 3110-3117, 2020 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31879782
2.
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Lancet
; 385(9987): 2606-15, 2015 Jun 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-25890673
3.
Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial.
AIDS Res Ther
; 11: 39, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25926858
4.
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study.
Lancet HIV
; 11(3): e146-e155, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38307098
5.
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
Lancet HIV
; 10(1): e15-e23, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36566079
6.
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.
NEJM Evid
; 1(2): EVIDoa2100043, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38319179
7.
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide.
AIDS
; 32(12): 1723-1725, 2018 07 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-29794828
8.
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.
Lancet HIV
; 5(7): e347-e356, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29925490
9.
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.
Lancet HIV
; 5(4): e162-e171, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29475804
10.
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Lancet HIV
; 4(4): e154-e160, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28219610
11.
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Lancet HIV
; 4(5): e205-e213, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28259776
12.
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Lancet HIV
; 4(5): e195-e204, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28259777
13.
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
J Acquir Immune Defic Syndr
; 73(3): 294-298, 2016 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27171740
14.
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
J Acquir Immune Defic Syndr
; 71(5): 530-7, 2016 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26627107
15.
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
J Acquir Immune Defic Syndr
; 69(4): 439-45, 2015 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25867913
16.
Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults.
J Int AIDS Soc
; 17(4 Suppl 3): 19772, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25397516
Resultados
1 -
16
de 16
1
Próxima >
>>